A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 2
Healthy Volunteers: f
View:
• Positive glucose hydrogen breath test (GHBT)
• Weight-for-age Z score \> -1
• Length-for-age Z score \> -1
Locations
Other Locations
Bangladesh
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
RECRUITING
Dhaka
Contact Information
Primary
Jeffrey R Donowitz, MD
jrd9d@virginia.edu
434-243-8824
Time Frame
Start Date: 2026-04-18
Estimated Completion Date: 2026-12-02
Participants
Target number of participants: 60
Treatments
Experimental: Metronidazole
14-day oral course
Experimental: Trimethoprim-sulfamethoxazole and Metronidazole
14-day oral course
Experimental: Amoxicillin-Clavulanate
14-day oral course
Related Therapeutic Areas
Sponsors
Collaborators: International Centre for Diarrhoeal Disease Research, Bangladesh, Virginia Commonwealth University, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Leads: University of Virginia